Investigation for the relationships between treatment resistant psychiatric patients and anti-NMDA receptor antibody encephalitis.

Investigation for the relationships between treatment resistant psychiatric patients and anti-NMDA receptor antibody encephalitis. - Investigation for the relationships between treatment resistant psychiatric patients and anti-NMDA receptor antibody encephalitis.

Status

Recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000014717

Enrollment

100

Registered

2014-08-01

Start date

2014-08-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Treatment resistant psychiatric disease, anti-NMDA receptor antibody encephalitis

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Psychiatric patients who did not remitted by the standard more than 2 medications. Normal controls are healthy volunteers.

Exclusion criteria

Exclusion criteria: Psychiatric patients who were treated by less than 1 standard psychiatric medication.

Design outcomes

Primary

Measure	Time frame
Demographic information of the targets are age, gender, psychiatric symptoms, disease duration and psychiatric diagnosis. Clinical symptoms include disturbance of consciousness, convulsions, disorientation, impaired short-term memory, anarithmia, configuration failure, hallucinations, delusions, anxiety, depression, emotional lability, personality change, gait disturbance, bradykinesia, muscular rigidity, tremor and Katatonia. Blood tests include general blood tests, autoantibodies such as TG and TPO antibodies and thyroid function tests (TSH fT3 fT4). Anti-neuronal antibodies are anti-NMDA-NR1 and NR2 antibody. Cerebrospinal fluid tests includes general examination, anti-NMDA-NR1 and NR2 antibody. Imaging and physiological function tests are head MRI examination, head SPECT and EEG. Psychological tests are cognitive function test such as WAIS-III, WMS-R, WCST, MMSE, and HDS-R. Psychiatric evaluation includes PANSS and BPRS. (We use the data that is listed in the medical record) For the normal volunteer, we perform blood tests, head MRI examination and psychological examination. Cerebrospinal fluid examination is performed when the consent was obtained from the volunteer.	—

Measure

Time frame

Demographic information of the targets are age, gender, psychiatric symptoms, disease duration and psychiatric diagnosis. Clinical symptoms include disturbance of consciousness, convulsions, disorientation, impaired short-term memory, anarithmia, configuration failure, hallucinations, delusions, anxiety, depression, emotional lability, personality change, gait disturbance, bradykinesia, muscular rigidity, tremor and Katatonia. Blood tests include general blood tests, autoantibodies such as TG and TPO antibodies and thyroid function tests (TSH fT3 fT4). Anti-neuronal antibodies are anti-NMDA-NR1 and NR2 antibody. Cerebrospinal fluid tests includes general examination, anti-NMDA-NR1 and NR2 antibody. Imaging and physiological function tests are head MRI examination, head SPECT and EEG. Psychological tests are cognitive function test such as WAIS-III, WMS-R, WCST, MMSE, and HDS-R. Psychiatric evaluation includes PANSS and BPRS. (We use the data that is listed in the medical record) For the normal volunteer, we perform blood tests, head MRI examination and psychological examination. Cerebrospinal fluid examination is performed when the consent was obtained from the volunteer.

—

Secondary

Measure	Time frame
Correlation between the titer of the anti-NMDA receptor antibodies and the clinical symptoms, clinical diagnosis, the results of laboratory and imaging examination.	—

Countries

Japan

Contacts

Public ContactYuhei Chiba

Yokohama city university hospital Department of psychiatry

yu_chiba@yokohama-cu.ac.jp045-787-2800

Outcome results